Global Breast Cancer Drug Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2023 –2030 |
 Tamanho do mercado (ano base ) | USD 30,247.54 Million |
 Tamanho do mercado ( Ano de previsão) | USD 55,996.57 Million |
 CAGR |
% |
| Principais participantes do mercado |
|
>Mercado global de medicamentos para o cancro da mama, por tipo de produto (medicamento, quimioterapia, terapia dirigida, radioterapia e outros), tipo de cancro (carcinoma ductal invasivo (IDC), carcinoma lobular invasivo (ILC), cancro da mama inflamatório, doença de Paget do mamilo , Angiossarcoma da mama, tumores filoides da mama, tipos de cancro de mama não invasivos (in-situ), carcinoma ductal in situ (CDIS), carcinoma lobular in situ (LCIS), cancro de mama metastático e outros) , estádios (Estágio 0, Estágio I, Estágio II, Estágio III e Estágio IV), Tipo de medicamento (Genérico e de marca), Faixa etária (geriátrico e adultos), Via de administração (oral e intravenosa), Utilizador final (hospitais , clínicas especializadas , Centros de Cancro e Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho e Farmácia Online) - Tendências e Previsões do Sector para 2030.
Análise e dimensão do mercado de medicamentos para o cancro da mama
A crescente incidência do cancro da mama em diferentes países está a impulsionar o crescimento do mercado. Espera-se que o mercado global de medicamentos contra o cancro da mama ganhe crescimento de mercado no período de previsão de 2023 a 2030.
A Data Bridge Market Research analisa que o mercado global de medicamentos contra o cancro da mama deverá atingir os 55.996,57 milhões de dólares até 2030, face aos 30.247,54 milhões de dólares em 2022, crescendo a um CAGR de 8,2% durante o período de previsão de 2023 a 2030.
|
Métrica de relatório |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Ano histórico |
2021 (personalizável 2015-2020) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Tipo de produto (medicamento, quimioterapia, terapêutica dirigida, radioterapia e outros), tipo de cancro (carcinoma ductal invasivo (CDI), carcinoma lobular invasivo (CIL), cancro inflamatório da mama, doença de Paget do mamilo, angiossarcoma da mama, filódios Tumores da mama, tipos de cancro da mama não invasivos (in-situ), carcinoma ductal in situ (CDIS), carcinoma lobular in situ (LCIS), cancro da mama metastático e outros), estádios (estádio 0, estádio I, Estádio II, Estádio III e Estádio IV), Tipo de Medicamento (Genérico e de Marca), Faixa Etária (Geriátrica e Adultos), Via de Administração (Oral e Endovenosa), Utilizador Final (Hospitais, Clínicas Especializadas, Centros de Cancro e Outros) , Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho e Farmácia Online) |
|
Países abrangidos |
EUA, Canadá, México, Alemanha, França, Reino Unido, Itália, Espanha, Holanda, Rússia, Suíça, Turquia, Resto da Europa, China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas , Resto da Ásia-Pacífico, Brasil, Argentina, Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito e Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, Eisai Co., Ltd., Mylan N.V. (A Subsidiary of Viatris Inc.), Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd., MacroGenics, Inc., Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, and AbbVie Inc. |
Market Definition
Breast cancer is a condition due to the unchecked proliferation of malignant cells in the breast tissue. It can be treated by medications that are made to target and block the development of cancer cells, reduce tumor size, and stop the spread of cancer to other body regions. In addition to this, a number of additional treatment options are also available, including radiation therapy, chemotherapy, and hormone therapy.
The kind and stage of breast cancer, the presence of particular molecular markers, and the unique characteristics of the patient all play a role in the decision of which breast cancer drug(s) to use. Plans for treating patients can be made specifically for each one and may include a combination of these medications. The best possible outcome is sought after with breast cancer drug therapy, which may entail total remission, tumor reduction, or halting the disease's course while limiting adverse effects.
Global Breast Cancer Drugs Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Advancement in Drugs Associated with Breast Cancer Treatment
Innovation in drug development has been a transformative force in the global breast cancer drugs market, driving advancements in treatment options and significantly improving patient outcomes. Breast cancer is one of the most prevalent and deadly cancers globally, making it a key focus area for pharmaceutical research and development. The continuous evolution of therapies and treatment approaches has enhanced the quality of care and propelled market growth.
One of the most notable innovations in breast cancer drug development is the advent of targeted therapies. These drugs are designed to specifically target the molecular and genetic characteristics of the tumour of an individual, resulting in more precise and effective treatment. The development of drugs such as Herceptin, which targets the HER2 protein, and CDK4/6 inhibitors such as Palbociclib, have revolutionized the management of breast cancer, leading to significantly improved survival rates and reduced side effects. Thus, the continuous innovation in drug development in breast cancer treatment, offering new avenues for improved patient outcomes and a brighter future in the fight against this devastating disease, is driving the market growth.
- Increasing Incidence of Breast Cancer across Different Countries
In recent years, a concerning trend has emerged across various countries associated with the incidence of breast cancer. This rise is a result of many factors, including changing lifestyles, dietary habits, hormonal imbalances, delayed childbearing, and increased life expectancy. Modern-day sedentary lifestyles, high consumption of processed foods, limited physical activity, exposure to environmental pollutants, and the prevalence of certain genetic predispositions have collectively contributed to the growing incidence of breast cancer.
The increasing incidence of breast cancer is not only affecting the pharmaceutical sector but also influencing healthcare systems and policies. Governments and healthcare organizations are intensifying efforts to enhance early detection programs, education initiatives, and screening campaigns. These initiatives are crucial in addressing the rising burden of breast cancer, ensuring timely diagnosis, and promoting proactive approaches to treatment. Furthermore, as the demand for breast cancer drugs continues to surge, collaboration between pharmaceutical companies, research institutions, and healthcare providers becomes vital to accelerate the development and accessibility of cutting-edge treatments for breast cancer patients worldwide, which is driving the market growth.
Opportunity
- Government Initiatives and Other Funding Sources for Cancer Research
Governments worldwide recognized the immense healthcare and economic burden and took some initiatives and investments in R&D efforts. Government grants and funding programs enable pharmaceutical companies and research institutions to explore innovative treatments, test drug’s efficacy, and bring new drugs to market. This research often results in discovering more effective and less toxic breast cancer drugs, expanding the treatment options available to patients.
Government-sponsored initiatives emphasize the importance of early detection and prevention through public awareness campaigns and screening programs. These efforts lead to earlier diagnosis and intervention, potentially reducing the healthcare cost associated with advanced-stage breast cancer treatment. Moreover, the emphasis on cancer research fosters collaborations between academia, industry, and healthcare providers, facilitating the translation of scientific advancements into practical treatments for patients.
In addition to government initiatives, private and nonprofit organizations also play a pivotal role in funding cancer research. The availability of diverse funding sources further fuels the development of innovative therapies, making the market a dynamic and growing sector. Ultimately, the concerted efforts of governments and various funding sources promise to improve breast cancer care, and enhance patient outcomes, which is expected to create opportunity for market growth.
Restraint/Challenge
- Rising Cost of Drugs Associated with Cancer Treatment
The drugs associated with cancer treatment often come with high price tags, putting an immense financial burden on patients and healthcare systems, as innovative and targeted therapies continue to emerge.
Primarily, the high cost of these drugs limits patient access to advance treatments. Despite of proven outcomes most of the patients cannot afford the treatment. Patients without adequate insurance coverage or in countries with limited access to these expensive drugs may face barriers to receiving the most effective treatments, resulting in unequal outcomes in breast cancer management. In addition, the financial strain extends to healthcare systems and insurers. The budgetary pressures of covering expensive cancer drugs can divert resources from other essential healthcare needs. This diversion of funds can have broader implications for healthcare equity and the overall sustainability of healthcare systems.
Furthermore, the rising drug prices can lead to unaffordable expenses for patients, causing financial toxicity. Patients may delay or forget treatment due to these drugs' unaffordability, which can negatively impact their health and overall prognosis. This, in turn, may reduce the demand for these drugs in the market, which is restraining the market growth.
Global Breast Cancer Drugs Market Scope
The global breast cancer drugs market is segmented into eight notable segments based on product type, cancer type, stages, drug type, age group, route of administration, end user, and distribution channel.
Product Type
- Medication
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Others
On the basis of product type, the market is segmented into medication, chemotherapy, targeted therapy, radiation therapy, and others.
Cancer Type
- Invasive Ductal Carcinoma (IDC)
- Invasive Lobular Carcinoma (ILC)
- Inflammatory Breast Cancer
- Paget's Disease of the Nipple
- Angiosarcoma of the Breast
- Phyllodes Tumors of the Breast
- Noninvasive (in-situ) Types of Breast Cancer
- Ductal Carcinoma in Situ (DCIS)
- Lobular Carcinoma in Situ (LCIS)
- Metastatic Breast Cancer
- Others
On the basis of cancer type, the market is segmented into Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), inflammatory breast cancer, paget's disease of the nipple, angiosarcoma of the breast, phyllodes tumors of the breast, non-invasive (In-situ) types of breast cancer, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), metastatic breast cancer, and others.
Stages
- Stage 0
- Stage I
- Stage II
- Strage III
- Stage IV
On the basis of stages, the market is segmented into stage 0, stage I, stage II, stage III, and stage IV.
Drug Type
- Generic
- Branded
On the basis of drug type, the market is segmented into generic and branded.
Age Group
- Geriatric
- Adults
On the basis of age group, the market is segmented into geriatric and adults.
Route of Administration
- Oral
- Intravenous
On the basis of route of administration, the market is segmented into oral and intravenous.
End User
- Hospitals
- Specialty Clinics
- Cancer Centers
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, cancer centers, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Global Breast Cancer Drugs Market Regional Analysis/Insights
The global breast cancer drugs market is analyzed, and market size insights and trends are provided by product type, cancer type, stages, drug type, age group, route of administration, end user, and distribution channel as referenced above.
The countries covered in the this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and rest of Middle East and Africa.
North America is expected to dominate the market as it comprises a large number of key companies and a huge network of suppliers and manufacturers. The U.S. is expected to dominate the market due to the continuous innovation in drug development in breast cancer treatment, offering new avenues for improved patient outcomes and a brighter future in the fight against this devastating disease. Germany in Europe is expected to dominate the market due to the increasing incidence of breast cancer, which is not only affecting the pharmaceutical sector but also influencing healthcare systems and policies. China in Asia-Pacific is expected to dominate the market due to growing awareness of the importance of hormone therapy in reducing the risk of recurrence, which is leading to its incorporation into standard treatment protocols.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Breast Cancer Drugs Market Share Analysis
O panorama competitivo do mercado global de medicamentos contra o cancro da mama fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas no mercado.
Alguns dos principais players que operam no mercado global de medicamentos contra o cancro da mama são a F. Hoffmann-La Roche Ltd, a Pfizer Inc., a AstraZeneca, a Novartis AG, a Eli Lilly and Company, a Merck & Co., Inc., a Sanofi, Bristol -Myers Squibb Company, Eisai Co., Ltd., Mylan NV (uma subsidiária da Viatris Inc.), Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd., MacroGenics, Inc., Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, e AbbVie Inc., entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BREAST CANCER DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 MULTIVARIATE MODELLING
2.9 PRODUCT TYPE LIFELINE CURVE
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 EPIDEMIOLOGY
4.4 PIPELINE ANALYSIS
5 REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 ADVANCEMENT IN DRUGS ASSOCIATED WITH BREAST CANCER TREATMENT
6.1.2 INCREASING INCIDENCE OF BREAST CANCER ACROSS DIFFERENT COUNTRIES
6.1.3 INCREASING DEVELOPMENT IN THE FIELD OF TARGETED THERAPY FOR BREAST CANCER
6.1.4 INCREASING USAGE OF HORMONE THERAPY IN BREAST CANCER TREATMENT
6.1.5 GROWING NUMBER OF SCREENING PROGRAMS RELATED TO BREAST CANCER
6.2 RESTRAINTS
6.2.1 RISING COST OF DRUGS ASSOCIATED WITH CANCER TREATMENT
6.2.2 ADVERSE SIDE EFFECTS AND COMPATIBILITY CONCERNS
6.3 OPPORTUNITIES
6.3.1 GOVERNMENT INITIATIVES AND OTHER FUNDING SOURCES FOR CANCER RESEARCH
6.3.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DEVELOPMENT
6.3.3 USAGE OF ADJUVANT THERAPIES
6.4 CHALLENGES
6.4.1 COMPLICATIONS ASSOCIATED WITH CHEMOTHERAPY
6.4.2 LACK IN EARLY DETECTION OF BREAST CANCER
7 GLOBAL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 ANASTROZOLE (ARIMIDEX)
7.2.2 CYCLOPHOSPHAMIDE (CYTOXAN)
7.2.3 EXEMESTANE (AROMASIN)
7.2.4 LETROZOLE (FEMARA)
7.2.5 OTHERS
7.3 CHEMOTHERAPY
7.3.1 FLUOROURACIL
7.3.2 METHOTREXATE
7.3.3 PACLITAXEL
7.3.4 EPIRUBICIN
7.3.5 DOCETAXEL
7.3.6 OTHERS
7.4 RADIATION THERAPY
7.5 TARGETED THERAPY
7.5.1 PEMBROLIZUMAB
7.5.2 OLAPARIB
7.5.3 LAPROTRECTINIB
7.5.4 ENTRECTINIB
7.5.5 OTHERS
7.6 OTHERS
8 GLOBAL BREAST CANCER DRUGS MARKET, BY STAGES
8.1 OVERVIEW
8.2 STAGE I
8.3 STAGE II
8.4 STAGE 0
8.5 STAGE III
8.6 STAGE IV
9 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERIC
10 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 GERIATRIC
10.3 ADULTS
11 GLOBAL BREAST CANCER DRUGS MARKET, BY CANCER TYPE
11.1 OVERVIEW
11.2 INVASIVE DUCTAL CARCINOMA (IDC)
11.3 INVASIVE LOBULAR CARCINOMA (ILC)
11.4 INFLAMMATORY BREAST CANCER
11.5 PAGET’S DISEASE OF THE NIPPLE
11.6 ANGIOSARCOMA OF THE BREAST
11.7 PHYLLODES TUMORS OF THE BREAST
11.8 NONINVASIVE (IN-SITU) TYPES OF BREAST CANCER
11.9 DUCTAL CARCINOMA IN SITU (DCIS)
11.1 LOBULAR CARCINOM AIN SITU (LCIS)
11.11 METASTATIC BREAST CANCER
11.12 OTHERS
12 GLOBAL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS
12.3 ORAL
13 GLOBAL BREAST CANCER DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CANCER CENTERS
13.4 SPECIALTY CLINICS
13.5 OTHERS
14 GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 GLOBAL BREAST CANCER DRUGS MARKET, BY REGION
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 U.K.
15.3.3 ITALY
15.3.4 FRANCE
15.3.5 SPAIN
15.3.6 SWITZERLAND
15.3.7 BELGIUM
15.3.8 NETHERLANDS
15.3.9 RUSSIA
15.3.10 TURKEY
15.3.11 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 AUSTRALIA
15.4.3 SOUTH KOREA
15.4.4 CHINA
15.4.5 INDIA
15.4.6 THAILAND
15.4.7 INDONESIA
15.4.8 MALAYSIA
15.4.9 SINGAPORE
15.4.10 PHILIPPINES
15.4.11 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 ARGENTINA
15.5.2 BRAZIL
15.5.3 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 EGYPT
15.6.3 U.A.E.
15.6.4 SAUDI ARABIA
15.6.5 REST OF MIDDLE EAST AND AFRICA
16 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
17 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 EUROPE BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 ASIA-PACIFIC BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMAPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 PFIZER INC.
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMAPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 ASTRAZENECA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMAPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 NOVARTIS AG
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMAPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 ELI LILLY AND COMPANY
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMAPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 ABBVIE, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 BRISTOL-MYERS SQUIBB COMPANY
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 EISAI CO., LTD
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 KYOWA KIRIN CO., LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 MERCK & CO., INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 MACROGENICS, INC.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 SANOFI
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 TEVA PHARMACEUTICAL INDUSTRIES LTD
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 VIATRIS INC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 GILEAD SCIENCES, INC
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL BREAST CANCER DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 GLOBAL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL MEDICATION IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL RADIATION THERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL BREAST CANCER DRUGS MARKET, BY STAGES, 2022-2030 (USD MILLION)
TABLE 12 GLOBAL STAGE I IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL STAGE II IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL STAGE 0 IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL STAGE III IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL STAGE IV IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL BRANDED IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL GENERIC IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL GERIATRIC IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL ADULTS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL INVASIVE DUCTAL CARCINOMA (IDC) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL INVASIVE LOBULAR CARCINOMA (ILC) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL INFLAMMATORY BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL PAGET’S DISEASE OF THE NIPPLE IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL ANGIOSARCOMA OF THE BREAST IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL PHYLLODES TUMORS OF THE BREAST IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL NONINVASIVE (IN SITU) TYPES OF BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL DUCTAL CARCINOMA IN SITU (DCIS) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL LOBULAR CARCINOMA IN SITU (LCIS) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL METASTATIC BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL INTRAVENOUS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 GLOBAL ORAL IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 GLOBAL BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 39 GLOBAL HOSPITALS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 GLOBAL CANCER CENTERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 GLOBAL SPECIALTY CLINICS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 44 GLOBAL HOSPITAL PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 GLOBAL RETAIL PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 GLOBAL ONLINE PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 GLOBAL BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 60 U.S. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 66 U.S. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 68 U.S. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 69 U.S. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 U.S. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 CANADA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 CANADA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 CANADA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 CANADA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 77 CANADA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 79 CANADA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 80 CANADA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 CANADA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 MEXICO BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 MEXICO MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 MEXICO CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 MEXICO TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 MEXICO BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 MEXICO BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 88 MEXICO BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 MEXICO BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 90 MEXICO BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 91 MEXICO BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 MEXICO BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 EUROPE BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 94 EUROPE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 EUROPE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 EUROPE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 EUROPE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 EUROPE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 99 EUROPE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 100 EUROPE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 101 EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 102 EUROPE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 103 EUROPE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 104 EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 GERMANY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 GERMANY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 GERMANY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 111 GERMANY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 112 GERMANY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 114 GERMANY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 GERMANY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 U.K. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.K. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 U.K. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 U.K. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 U.K. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 121 U.K. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 122 U.K. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 U.K. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 124 U.K. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 125 U.K. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 U.K. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 ITALY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 ITALY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 ITALY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 130 ITALY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 131 ITALY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 132 ITALY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 133 ITALY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 ITALY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 135 ITALY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 136 ITALY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 137 ITALY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 138 FRANCE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 FRANCE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 FRANCE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 FRANCE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 FRANCE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 143 FRANCE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 144 FRANCE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 146 FRANCE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 FRANCE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 SPAIN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 SPAIN MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 SPAIN CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 SPAIN TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 SPAIN BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 154 SPAIN BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 155 SPAIN BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 156 SPAIN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 157 SPAIN BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 158 SPAIN BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 159 SPAIN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 160 SWITZERLAND BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 SWITZERLAND MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 SWITZERLAND CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 163 SWITZERLAND TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 164 SWITZERLAND BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 165 SWITZERLAND BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 166 SWITZERLAND BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 167 SWITZERLAND BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 168 SWITZERLAND BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 169 SWITZERLAND BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 170 SWITZERLAND BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 171 BELGIUM BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 BELGIUM MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 BELGIUM CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 174 BELGIUM TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 175 BELGIUM BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 176 BELGIUM BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 177 BELGIUM BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 BELGIUM BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 179 BELGIUM BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 BELGIUM BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 181 BELGIUM BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 182 NETHERLANDS BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 NETHERLANDS MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 184 NETHERLANDS CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 185 NETHERLANDS TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 186 NETHERLANDS BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 187 NETHERLANDS BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 188 NETHERLANDS BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 NETHERLANDS BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 190 NETHERLANDS BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 191 NETHERLANDS BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 192 NETHERLANDS BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 193 RUSSIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 194 RUSSIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 195 RUSSIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 196 RUSSIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 197 RUSSIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 198 RUSSIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 199 RUSSIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 200 RUSSIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 201 RUSSIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 202 RUSSIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 203 RUSSIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 204 TURKEY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 TURKEY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 206 TURKEY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 207 TURKEY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 208 TURKEY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 209 TURKEY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 210 TURKEY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 211 TURKEY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 212 TURKEY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 TURKEY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 214 TURKEY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 215 REST OF EUROPE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 217 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 ASIA-PACIFIC MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 ASIA-PACIFIC CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 ASIA-PACIFIC TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 222 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 223 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 225 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 226 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 227 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 228 JAPAN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 229 JAPAN MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 230 JAPAN CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 JAPAN TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 JAPAN BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 233 JAPAN BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 234 JAPAN BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 JAPAN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 236 JAPAN BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 JAPAN BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 238 JAPAN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 239 AUSTRALIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 240 AUSTRALIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 241 AUSTRALIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 242 AUSTRALIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 243 AUSTRALIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 244 AUSTRALIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 245 AUSTRALIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 246 AUSTRALIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 247 AUSTRALIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 248 AUSTRALIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 249 AUSTRALIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 250 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 251 SOUTH KOREA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 252 SOUTH KOREA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 SOUTH KOREA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 254 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 255 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 256 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 257 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 258 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 259 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 260 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 261 CHINA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 262 CHINA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 263 CHINA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 264 CHINA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 265 CHINA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 266 CHINA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 267 CHINA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 CHINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 269 CHINA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 270 CHINA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 271 CHINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 272 INDIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 273 INDIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 274 INDIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 275 INDIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 276 INDIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 277 INDIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 278 INDIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 INDIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 280 INDIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 281 INDIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 282 INDIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 THAILAND BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 284 THAILAND MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 285 THAILAND CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 286 THAILAND TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 287 THAILAND BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 288 THAILAND BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 289 THAILAND BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 THAILAND BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 291 THAILAND BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 292 THAILAND BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 293 THAILAND BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 294 INDONESIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 295 INDONESIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 296 INDONESIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 297 INDONESIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 298 INDONESIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 299 INDONESIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 300 INDONESIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 301 INDONESIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 302 INDONESIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 303 INDONESIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 304 INDONESIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 305 MALAYSIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 306 MALAYSIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 307 MALAYSIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 308 MALAYSIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 309 MALAYSIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 310 MALAYSIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 311 MALAYSIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 312 MALAYSIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 313 MALAYSIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 314 MALAYSIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 315 MALAYSIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 316 SINGAPORE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 317 SINGAPORE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 318 SINGAPORE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 319 SINGAPORE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 320 SINGAPORE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 321 SINGAPORE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 322 SINGAPORE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 SINGAPORE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 324 SINGAPORE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 325 SINGAPORE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 326 SINGAPORE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 327 PHILIPPINES BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 328 PHILIPPINES MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 329 PHILIPPINES CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 330 PHILIPPINES TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 331 PHILIPPINES BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 332 PHILIPPINES BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 333 PHILIPPINES BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 PHILIPPINES BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 335 PHILIPPINES BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 336 PHILIPPINES BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 337 PHILIPPINES BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 338 REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 339 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 340 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 341 SOUTH AMERICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 342 SOUTH AMERICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 343 SOUTH AMERICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 344 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 345 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 346 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 347 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 348 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 349 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 350 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 351 ARGENTINA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 352 ARGENTINA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 353 ARGENTINA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 354 ARGENTINA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 355 ARGENTINA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 356 ARGENTINA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 357 ARGENTINA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 358 ARGENTINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 359 ARGENTINA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 360 ARGENTINA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 361 ARGENTINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 362 BRAZIL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 363 BRAZIL MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 364 BRAZIL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 365 BRAZIL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 366 BRAZIL BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 367 BRAZIL BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 368 BRAZIL BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 BRAZIL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 370 BRAZIL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 371 BRAZIL BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 372 BRAZIL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 373 REST OF SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 374 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 375 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 376 MIDDLE EAST AND AFRICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 377 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 378 MIDDLE EAST AND AFRICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 379 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 380 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 381 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 383 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 384 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 385 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 386 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 387 SOUTH AFRICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 388 SOUTH AFRICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 389 SOUTH AFRICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 390 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 391 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 392 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 393 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 394 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 395 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 396 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 397 EGYPT BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 398 EGYPT MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 399 EGYPT CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 400 EGYPT TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 401 EGYPT BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 402 EGYPT BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 403 EGYPT BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 404 EGYPT BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 405 EGYPT BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 406 EGYPT BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 407 EGYPT BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 408 U.A.E. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 409 U.A.E. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 410 U.A.E. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 411 U.A.E. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 412 U.A.E. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 413 U.A.E. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 414 U.A.E. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 415 U.A.E. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 416 U.A.E. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 417 U.A.E. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 418 U.A.E. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 419 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 420 SAUDI ARABIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 421 SAUDI ARABIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 422 SAUDI ARABIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 423 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 424 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 425 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 426 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 427 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 428 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 429 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL BREAST CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 GLOBAL BREAST CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BREAST CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BREAST CANCER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BREAST CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BREAST CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL BREAST CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL BREAST CANCER DRUGS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL BREAST CANCER DRUGS MARKET AND ASIA-PACIFIC REGION GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 RISING INCIDENCE OF BREAST CANCER IS DRIVING THE GROWTH OF GLOBAL BREAST CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BREAST CANCER DRUGS MARKET IN 2023 & 2030
FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR BREAST CANCER DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL BREAST CANCER DRUGS MARKET
FIGURE 15 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, 2022
FIGURE 16 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 17 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 18 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES , 2022
FIGURE 20 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, 2023-2030 (USD MILLION)
FIGURE 21 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 22 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 23 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 24 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 25 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, 2022
FIGURE 28 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 29 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 30 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, 2022
FIGURE 32 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 33 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 34 GLOBAL BREAST CANCER DRUGS MARKET: BY T CANCER TYPE, LIFELINE CURVE
FIGURE 35 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 36 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 37 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 38 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 39 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, 2022
FIGURE 40 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 41 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 45 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 GLOBAL BREAST CANCER DRUGS MARKET: SNAPSHOT (2022)
FIGURE 48 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 49 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 50 EUROPE BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 51 AISA-PACIFIC BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
